CoChat

Immunomodulatory therapies delay disease progression in multiple sclerosis

The DOI matches its Crossref record, with a small difference in title or year; 38 of the 38 references it cites were found in a registry or an index.

Abstract

Background Few studies have analysed long-term effects of immunomodulatory disease modifying drugs (DMDs). Objective Assessment of the efficacy of DMDs on long-term evolution of multiple sclerosis, using a Bayesian approach to overcome methodological problems related to open-label studies. Methods MS patients from three different Italian multiple sclerosis centres were divided into subgroups according to the presence of treatment in their disease history before the endpoint, which was represented by secondary progression. Patients were stratified on the basis of the risk score BREMS (Bayesian risk estimate for multiple sclerosis), which is able to predict the unfavourable long-term evolution of MS at an early stage. Results We analysed data from 1178 patients with a relapsing form of multiple sclerosis at onset and at least 10 years of disease duration, treated (59%) or untreated with DMDs. The risk of secondary progression was significantly lower in patients treated with DMDs, regardless of the initial prognosis predicted by BREMS. Conclusions DMDs significantly reduce the risk of multiple sclerosis progression both in patients with initial high-risk and patients with initial low-risk. These findings reinforce the role of DMDs in modifying the natural course of the disease, suggesting that they have a positive effect not only on the inflammatory but also on the neurodegenerative process. The study also confirms the capability of the BREMS score to predict MS evolution.

Overview

Integrity signals

Registry

Crossref · 10.1177/1352458512445941

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 4

  1. IFNB Multiple Sclerosis Study Group, 2001, Neurology, 57, S3
  2. Johnson KP, 2001, Neurology, 57, S16
  3. Theobald K, 2009, Ger Med Sci, 7
  4. Berzuini C, 1996, IEEE Trans Patt Anal Machine Intell, 2, 109-110

Cited by

See all 71

Metadata

Authors
Bergamaschi, R., Quaglini, S., Tavazzi, E., Amato, M. P., Paolicelli, D., Zipoli, V., Romani, A., Tortorella, C., Portaccio, E., D’Onghia, M., Garberi, F., Bargiggia, V., & Trojano, M.
Affiliations
  • Fondazione Istituto Neurologico Nazionale Casimiro Mondino (IT)
  • University of Pavia (IT)
  • University of Florence (IT)
  • University of Bari Aldo Moro (IT)
  • Department of Neurological and Psychiatric Sciences, University of Bari, Italy
Corresponding author
Bergamaschi, Roberto
Venue
Multiple Sclerosis Journal
Published
2016-07-20
Volume
22
Issue
13
Pages
1732-1740
ISSN
  • 1352-4585 (ISSN-L)
  • 1477-0970
OpenAlex
W2055317435
Cited by
71
References
38
Citations by year
2026: 4 · 2025: 2 · 2024: 3 · 2023: 3 · 2022: 5 · 2021: 6 · 2020: 8 · 2019: 11 · 2018: 3 · 2017: 2 · 2016: 4
FWCI
4.60
Type
journal article
Language
en
Open access
closed
Licence
journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations
  • Multiple Sclerosis Journal (publishedVersion)
  • PubMed (publishedVersion)
  • Florence Research (University of Florence) (submittedVersion)
  • CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion)
Topics
  • Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
  • Health Sciences › Medicine › Oncology › Polyomavirus and related diseases
  • Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
Keywords
multiple sclerosis, disease-modifying drugs, immunomodulatory therapy, relapsing multiple sclerosis, Bayesian risk estimation, long-term disease course, neurodegeneration, treatment response prediction
MeSH terms
Adult, Female, Follow-Up Studies, Humans, Immunotherapy, Male, Middle Aged, Prognosis, Severity of Illness Index, Outcome Assessment, Health Care, Disease Progression, Multiple Sclerosis, Relapsing-Remitting

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.